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A Meta-Analysis of 17 Randomized Trials of a
Percutaneous Coronary Intervention-Based Strategy
in Patients With Stable Coronary Artery Disease
Albert Schömig, MD, Julinda Mehilli, MD, Antoinette de Waha, MD, Melchior Seyfarth, MD,
Jürgen Pache, MD, Adnan Kastrati, MD
Munich, Germany
Objectives This study assessed the impact on long-term mortality of percutaneous coronary intervention (PCI) versus medi-
cal treatment in patients with symptoms or signs of myocardial ischemia but no acute coronary syndrome.
Background The impact of PCI on the long-term prognosis of patients with stable coronary artery disease has not been established.
Methods We identified 17 randomized trials comparing a PCI-based invasive treatment strategy with medical treatment in
7,513 patients with symptoms or signs of myocardial ischemia but no acute coronary syndrome. Of these patients,
3,675 were assigned to the PCI group and 3,838 to the medical treatment group. The primary end point was all-
cause death. The length of follow-up was in the range between 12 and 122 months, 51 months on average.
Results In the PCI group, 271 patients died compared with 335 patients in the medical treatment group, which corre-
sponds to a 20% reduction in the odds ratio (OR) of all-cause death (OR: 0.80; 95% confidence interval [CI]: 0.64
to 0.99, p  0.263 for heterogeneity across the trials). Allocation to the PCI group was associated with a nonsig-
nificant 26% reduction in the OR of cardiac death (OR: 0.74, 95% CI: 0.51 to 1.06). In the PCI group, 319 pa-
tients had a nonfatal myocardial infarction after randomization compared with 357 patients in the medical
treatment group (OR: 0.90, 95% CI: 0.66 to 1.23).
Conclusions These findings suggest that a PCI-based invasive strategy may improve long-term survival compared with a med-
ical treatment-only strategy in patients with stable coronary artery disease. (J Am Coll Cardiol 2008;52:
894–904) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.051c
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poronary artery disease is the single largest killer of American
en and women (1). In 2004 in the U.S., there were 840,000
ases discharged with the diagnosis of acute coronary syn-
rome, most of them with acute myocardial infarction (1). In
he last decades, important advances have been made, which
ave provided patients with coronary artery disease with
ffective drugs able to improve significantly their prognosis,
uch as antiplatelet agents, statins, beta-blockers, and
ngiotensin-converting enzyme inhibitors (2–4).
Percutaneous coronary interventions (PCIs) are increas-
ngly being used in patients with various manifestations of
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ccepted May 12, 2008.oronary artery disease. They represent an established treat-
ent strategy that improves survival and survival free of
ecurrent myocardial infarction in patients with ST-
egment elevation myocardial infarction (5,6). Early invasive
herapy also improves long-term survival and reduces late
yocardial infarction in patients with non–ST-segment
levation acute coronary syndromes (7). Although PCI
educes symptoms in patients without acute coronary syn-
romes (8), its effects on the prognosis of these patients are
till not defined. The assessment of this issue has been
ifficult for at least 2 reasons. First, patients with stable
oronary artery disease have a very good prognosis and large
ample size studies are required to assess potential dif-
erences in treatments regarding rare events (9,10). All
tudies performed to date were far from having sufficient
ower to assess mortality. Second, there is a certain risk
ssociated with PCI, which leads to aggregation of events
n a relatively short period after the procedure. Any
otential beneficial effect of PCI compared with medical
reatment alone may require time to offset this early
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ore unbiased evaluation of the relative merits of these
reatment strategies.
In an attempt to overcome these difficulties, 2 meta-
nalyses have been performed by pooling together the
esults from several randomized trials comparing invasive
nd medical treatment strategies in patients with no acute
oronary syndromes (11,12). The first meta-analysis sum-
arized the results of 6 trials including 1,904 patients, and
he analysis of mortality was based on 26 death cases (11);
he second meta-analysis summarized the results of 11 trials
ncluding 2,950 patients, and the analysis of mortality relied
n 196 death cases (12). Even in a recent brief update,
everal randomized clinical trials with a design similar to
hose already included were left unaccounted for in the latter
eta-analysis (13). This underscores the need for a new,
omprehensive meta-analysis of all pertinent studies on the
mpact of PCI on the prognosis of patients with stable
oronary artery disease.
The purpose of this meta-analysis was to evaluate
hether PCI affects the long-term prognosis of patients
ith stable coronary artery disease.
ethods
linical trial selection. We intended to retrieve all ran-
omized trials comparing a PCI-based invasive treatment
trategy with a medical treatment strategy in patients with
oronary artery disease and symptoms or signs of ischemia.
rials that included patients with acute coronary syndromes
with or without ST-segment elevation on electrocardio-
ram, with or without troponin or cardiac enzyme eleva-
ions) within the first week from presentation were excluded
rom this meta-analysis. The search was performed for the
eriod between January 1, 1980, through August 20, 2007,
nd involved the PubMed database, U.S. National Institute
f Health, Cochrane Central Register of Controlled Trials,
roceedings of the American Heart Association, Ameri-
an College of Cardiology, and European Society of
ardiology, as well as internet-based sources of informa-
ion on results of clinical trials in cardiology. Other data
ources included reference lists of retrieved articles, and
ertinent reviews and editorials from leading medical
ournals.
Nineteen randomized clinical trials were identified that
ssigned patients with no acute coronary syndromes to an
nvasive, PCI-based treatment strategy or medical-only
reatment strategy (14–32). In 2 of these trials (22,31),
either symptoms nor signs of myocardial ischemia were a
rerequisite for enrollment of patients in the study; thus,
hey were excluded from the present meta-analysis. Of the
7 trials included, 1 was published in abstract form (29) and
6 as full articles mostly presenting updated, extended
ollow-up (14–21,23–28,30,32). In 2 trials (23,30), patients
ere randomly assigned to 1 of 3 treatment groups: PCI,
edical treatment, or coronary artery bypass grafting pCABG); for both of these trials,
he CABG treatment arm was
ot included in this meta-
nalysis. However, patients who
ere randomly assigned to the
CI-based strategy or medical
reatment group but received
ABG were not excluded from
his meta-analysis.
utcome variables. The pri-
ary end point of this meta-analysis was all-cause death
ithin the longest follow-up period that was published by
he investigators. Other outcomes of interest were death
ttributable to cardiac causes and myocardial infarction. The
efinition of the end point of myocardial infarction is shown
n Table 1.
tatistical analysis. All trials included in this meta-analysis
ere prospective, randomized trials. The existence of an
ndependent event committee was declared by the investi-
ators of 12 of 17 trials (14–19,21,24–26,28,32). Baseline
haracteristics were evenly distributed between the 2 treat-
ent groups in all trials. The actual treatment received was
learly shown for all trials. In all but 2 trials (16,27), the
nalysis was performed on the basis of the intention-to-treat
rinciple. In the 2 trials that did not follow this principle, a
otal of 5 patients were excluded after randomization
16,27).
Treatment effect could not be assessed for trials in which
he event of interest was not observed in any of the
reatment groups. For trials in which only 1 of the treatment
roups had no events of interest, the treatment effect
stimate and its standard error were approximated from 2
contingency tables after adding 0.5 to each cell (33). We
sed the Cochran Q-test to assess heterogeneity across
rials. Also, we calculated the I2 statistic to measure the
onsistency between trials with values of 25%, 50%, and
5% defining the cutoff points for identifying low, moder-
te, and high degrees of heterogeneity, respectively (34).
reatment effects from individual trials were pooled using
oth the fixed effects Mantel-Haenszel model (35) and the
andom effects DerSimonian and Laird model (36). Several
dditional analyses were carried out to assess potential bias
egarding the primary end point of the study. First, sensi-
ivity analyses were performed by comparing the treatment
ffects obtained with each trial removed consecutively from
he analysis with the overall treatment effects. Second, a
unnel plot as well as the Egger test were used to assess
ublication bias (37). Third, a funnel plot was constructed
o graphically illustrate the relationship between treatment
ffect size and sample size of the individual trials. Finally, we
sed a random-effects meta-regression analysis to estimate
he extent to which other covariates—year of completion of
atient enrollment, total sample size of the trial, proportion
f patients with previous myocardial infarction, proportion
f patients who received stents or CABG in the PCI group,
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CI  confidence interval
OR  OR
PCI  percutaneous
coronary interventionroportion of patients who received non-protocol revascu-
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Table 1 Inclusion Criteria, Exclusion Criteria, and End Point Definitions of the Trials
Trial Inclusion Criteria Exclusion Criteria Primary End Point MI Definition
Sievers et al. (29) Previous non–Q-wave MI; single-vessel
disease of a major coronary artery, and
no angina in daily life under medication
Previous Q-wave MI, positive stress
test at 50 W, diabetes mellitus
NR NR
ACME 1 (19) Stable angina, markedly positive stress test,
or MI within 3 months, stenosis 70% in
the proximal 2/3 of a single vessel
Medically refractory unstable angina
pectoris, previous PCI, left main
artery stenosis 50%, 70%
stenosis at more than 1 artery,
EF 30%
Death, MI, recurrent
hospitalization for cardiac
disease, nonprotocol
revascularization
New Q waves, hospital
admission for chest
pain with serum
enzyme changes
ACME 2 (19) Stable angina, markedly positive stress test,
or MI within 3 months, stenosis 70% in
the proximal 2/3 of 2 vessels
Medically refractory unstable angina
pectoris, previous PCI, left main
artery stenosis 50%, 70%
stenosis at more than 2 arteries,
EF 30%
Death, MI, recurrent
hospitalization for cardiac
disease, nonprotocol
revascularization
New Q waves, hospital
admission for chest
pain with serum
enzyme changes
ACIP (17) Stable patients either free of angina or with
symptoms that could be well controlled
by medical therapy, by stress test, at
least 1 episode of asymptomatic
ischemia during 24-h ECG;
angiographically-documented coronary
artery disease
Recent MI (within 4 weeks),
unstable angina, CCS IV,
NYHA functional class III or IV,
PCI within 6 months, CABG within
3 months, left main artery stenosis
50%
Death, death or MI,
hospitalization for a cardiac
condition (including
nonprotocol
revascularization)
NR
Dakik et al. (16) Stable survivors of MI, large total (20%)
and ischemic (10%) LV perfusion
defect size
Clinical instability, EF 35%,
3-vessel disease, 50% left
main artery stenosis
Reduction of LV perfusion
defect
Increase in creatinine
kinase-MB with new
ST-segment changes
and/or chest pain
AVERT (28) LDL 115 mg/dl, triglycerides 500 mg.
MI or unstable angina but not within 14
days, CCS I, II angina or asymptomatic,
stenosis 50% in 1 or 2 vessels
Age 80 yrs, MI or unstable angina
pectoris within previous 2 weeks,
triple-vessel disease, left main
artery stenosis, EF 40%
Ischemic events (cardiac death,
cardiac arrest, MI,
cerebrovascular accident,
nonprotocol
revascularization, worsening
angina requiring
hospitalization)
NR
MASS (23) Stable angina, normal EF, inducible
ischemia; stenosis 80% before first
diagonal branch 12 mm in length
Prior revascularization, Q-wave MI,
LV dysfunction, total occluded or
tortuous or calcified lesions,
50% stenosis of left main
artery
Cardiac death, MI, refractory
angina requiring
hospitalization
New Q waves with
creatinine kinase-MB
enzyme increase 3
times its normal value
Bech et al. (14) CCS I or higher class angina, no evidence of
reversible ischemia (noninvasive testing
previous 2 months either negative,
inconclusive, or not performed),
significant de novo stenosis 50% in a
native coronary artery
Total occlusion, Q-wave MI or
unstable angina, small target
vessel 2.5 mm
All-cause death, MI,
revascularization, procedure-
related complication
New Q waves or increase
of serum creatinine
kinase levels to 2
times the normal limit
ALKK (32) Stable patients 8 to 42 days after
ST-segment elevation MI; CCS I, CCS II
angina pectoris, significant stenosis or
occlusion of native infarct-related artery
CCS III, IV angina, 70% stenosis in
noninfarct vessels, indication for
CABG
Survival free of reinfarction,
(re)intervention, CABG,
readmission for severe
angina
NR
RITA 2 (21) Stable or unstable angina leading to
admission, last episode at least 7 days
before enrollment, single or multivessel
disease, stenosis in at least 1 artery,
50% stenosis in 2 projections or 70%
stenosis in 1 projection
Left main artery disease, previous
revascularization, recent (7
days) acute coronary syndrome
All-cause death or MI New Q waves or
convincing clinical
history associated
with typical ECG
changes and serum
activities
TIME (27) Age 75 yrs with chronic CCS II angina or
higher, chest pain refractory to at least
2 antianginal drugs
Acute MI within previous 10 days Quality of life, major adverse
cardiac events (death, MI,
acute coronary syndrome)
Clinical event with
significant ECG and
enzyme changes
Hambrecht et al.
(20)
CCS I to III angina with documented
ischemia during stress test, 1 native
coronary artery stenosis 75%
Age 70 yrs, acute coronary
syndrome, recent MI
(2 months), EF 40%,
revascularization within past 12
months, left main artery stenosis
25% or high-grade stenosis of
left anterior descending artery
Angina-free exercise capacity, a
composite of cardiac death,
MI, stroke, revascularization,
worsening angina with
resulting hospitalization
NRContinued on next page
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nfluenced the treatment effect. All p values are 2-sided.
tatistical significance was assumed for p  0.05. Statistical
nalysis was performed using the Stata software, version 9.2
Stata Corp., College Station, Texas).
esults
able 1 shows inclusion and exclusion criteria as well as the
rimary end point in individual trials. A total of 17
andomized trials including 7,513 patients were analyzed.
able 2 shows the main characteristics of the patients in
ach trial. Overall, the average age of the patients was 60
ears, 18% of them were women, 54% had incurred myo-
ardial infarction, and the average length of follow-up was
1 months. Ninety-two percent of the patients in the
CI-based strategy group received revascularization (43%
alloon angioplasty, 41% stents, and 8% CABG). Drug-
luting stents were only used in 31 patients in 1 trial (15). In
he medical treatment group, 28% of the patients received
onprotocol revascularization early or at some point in time
uring follow-up.
In the PCI group, 271 patients died, compared with 335
atients in the medical treatment group. Allocation to the
CI group was associated with a 20% reduction in the odds
atio (OR) of all-cause death (Fig. 1). There was no
ontinued
Table 1 Continued
Trial Inclusion Criteria Exc
DANAMI (24) Inducible post-infarct ischemia, ability to
perform a symptom-limited bicycle
exercise
Drug-resistan
previous r
procedure
INSPIRE (25) Stable survivors of MI, total perfusion defect
size 20%, ischemic defect size 10%
(by adenosine SPECT), EF 35%
Cardiogenic s
pain, acut
with prima
functional
MASS II (30) Documented ischemia (stress testing or CCS
II or III angina), proximal multivessel
coronary stenosis 70%
Age 80 yrs
acute MI,
revascular
disease, le
50%
SWISSI II (18) First MI within preceding 3 months, no chest
pain at maximal symptom-limited
exercise test, sign of silent ischemia
(confirmed by stress imaging), 1- or
2-vessel disease
COURAGE (15) CCS I, CCS II angina, or initial CCS IV angina
stabilized medically, stable post-MI,
objective evidence of ischemia, stenosis
70% in at least 1 proximal coronary
artery, and objective evidence of
ischemia or at least 1 stenosis 80%
and classic angina without provocative
testing
Age 69 yrs
angina, m
test, refra
cardiogen
revascular
months, u
artery sten
CIP  Asymptomatic Cardiac Ischemia Pilot study; ACME  Angioplasty Compared to Medicine
torvastatin versus Revascularization Treatment study; CABG  coronary artery bypass surgery; C
ggressive Drug Evaluation study; DANAMI  Danish Multicenter Randomized Study of Invasive Ve
nfarction study; ECG electrocardiogram; EF ejection fraction; INSPIRE Adenosine Sestamib
Imyocardial infarction; NR not reported; NYHA New York Heart Association; PCI percutan
I  Swiss Interventional Study on Silent Ischemia Type II; TIME  Randomized Trial of Invasive Vnconsistency across the trials (I2  17%). The sensitivity analysis yielded ORs that ranged from 0.76 (95% confidence
nterval [CI]: 0.60 to 0.96) to 0.86 (95% CI: 0.72 to 1.03)
hat were not significantly different from the overall OR (p
0.591). Figure 2A shows the funnel plot of publication
ias, which was not statistically significant (p  0.261) on
he basis of the Egger test. Figure 2B shows that there was
o relationship between sample size and treatment effect
ize. None of the covariates—year of completion of patient
nrollment (p  0.982), total sample size of the trial (p 
.634), proportion of patients with previous myocardial
nfarction (p  0.119), proportion of patients in the PCI
roup who received stents (p  0.9361) or CABG (p 
.392), and proportion of patients in the medical treatment
roup who received nonprotocol revascularization (p 
.652)—showed a significant interaction with treatment
ffect.
A separate analysis was performed to investigate the role
f length of follow-up. We assessed all-cause death after
ollow-up periods of up to 1 year, 3 years, and 5 years, and
dded these data to our overall analysis, encompassing a
ollow-up period of up to 10 years. For this purpose, we
ought additional information on earlier mortality in the
rials from initial publications (38–42) or directly from
nvestigators (18). Figure 3 shows the relationship between
he length of follow-up and the ORs of all-cause death
Criteria Primary End Point MI Definition
na pectoris,
larization
Death, reinfarction, admission
with unstable angina, and
combination
New Q waves in at least
2 ECG leads
recurrent chest
nary syndrome
, NYHA
III and IV
Reduction of LV perfusion
defect
NR
ble angina,
0%, previous
, single-vessel
in artery stenosis
Overall mortality, Q-wave MI,
refractory angina requiring
revascularization
New Q waves, symptoms
compatible with MI
associated with
creatine kinase-MB
3 times the upper
limit
Survival free of major adverse
cardiac events (cardiac
death, MI, symptom-driven
revascularization)
Typical chest pain,
ST-segment elevation,
typical increase of
cardiac enzymes
tent CCS IV
y positive stress
eart failure or
k, EF 30%,
within 6
cted left main
50%
Composite of death from any
cause or MI
Acute coronary
syndrome with new
Q waves or positive
cardiac markers
ALKK  Study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte; AVERT 
Canadian Cardiovascular Society; COURAGE  Clinical Outcomes Utilizing Revascularization and
nservative Treatment in Patients With Inducible Ischemia After Thrombolysis in Acute Myocardial
nfarction Evaluation study; LV  left ventricular; MASS Medicine, Angioplasty, or Surgery Study;
ronary intervention; RITA 2 Second randomized Intervention Treatment of Angina study; SWISSI
edical Therapy in Elderly Patients.lusion
t angi
evascu
hock,
e coro
ry PCI
class
, unsta
EF 4
ization
ft ma
NR
, persis
arkedl
ctory h
ic shoc
ization
nprote
osis 
study;
CS 
rsus Co
i Post-Issociated with PCI versus medical treatment.
MAbbreviations as in Table 1.
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Trial
Sievers et al.
Dakik et al.
ACIP
ACME-1
TIME
ALKK
AVERT
Bech et al.
MASS
ACME-2
RITA-2
Year of Publication
1993
1998
1997
1997
2004
2003
1999
2001
1999
1997
2003
271/3675
PCI
0/44
1/21
2/192
16/115
45/153
6/149
1/177
2/90
6/72
9/51
43/504
335/3838
Medical
1/44
1/23
20/366
15/112
40/148
17/151
1/164
4/91
6/72
10/50
43/514
Deaths/Total
SWISSI II
DANAMI
COURAGE
INSPIRE
Hambrecht et al.
MASS II
2007
2006
2007
2006
2004
2006
6/96
19/503
85/1149
2/104
28/205
22/105
24/505
95/1138
1/101
35/203
0/50 0/51
1.1 10
Random effects model
Fixed effects model
Pheterogeneity=0.263; I
2=17%
Odds Ratio (95% Confidence Interval)
0.80 (0.64 to 0.99)
0.80 (0.68 to 0.95)
Figure 1 Odds Ratios for Mortality in Individual Trials Comparing the PCI-Based Strategy With Medical Treatment Strategy
Pooled odds ratios are also shown. PCI  percutaneous coronary intervention.ain Characteristics of the Trials
Table 2 Main Characteristics of the Trials
Trial
Year of
Most
Recent
Publication
Enrollment
Period
Total
No. of
Patients
Mean
Age
(yrs)
Women
(%)
Previous
MI (%)
Protocol
Revascularizations
in PCI Group (%)
Total (CABG)
Use of
Stents in
PCI Group
(%)
Nonprotocol
Revascularizations
in Medical Group (%)
Total (CABG)
Length of
Follow-Up
(Months)
Sievers et al. (29) 1993 NR 88 56 NR 55 100 (0) 0 20 (5) 24
ACME 1 (19) 1997 1987–1990 227 60 0 34 96 (0) 0 41 (11) 60
ACME 2 (19) 1997 1987–1990 101 60 0 45 100 (0) 0 40 (30) 60
ACIP (17) 1997 1991–1993 558 62 14 40 89 (41) 0 29 (22) 24
Dakik et al. (16) 1998 1995–1996 44 54 41 100 100 (0) 29 9 (9) 12
AVERT (28) 1999 1995–1996 341 58 16 42 94 (0) 28 12 (1) 20
MASS (23) 1999 1988–1991 144 65 42 0 100 (0) 0 17 (11) 60
Bech et al. (14) 2001 NR 181 61 36 25 100 (0) 46 7 (0) 24
ALKK (32) 2003 1994–1997 300 57 13 100 93 (0) 16 24 (NR) 52
RITA 2 (21) 2003 1992–1996 1,018 58 18 47 93 (0) 8 35 (12) 84
TIME (27) 2004 1996–2000 301 80 42 47 71 (20) 44 42 (NR) 48
Hambrecht et al. (20) 2004 1997–2001 101 60 0 46 100 (0) 100 6 (0) 12
DANAMI (24) 2006 1990–1994 1,008 57 18 100 82 (29) 0 20 (NR) 28
INSPIRE (25) 2006 1999–2002 205 64 24 100 67 (26) 39 26 (10) 60
MASS II (30) 2006 1995–2000 408 60 32 46 95 (0) 68 24 (15) 60
SWISSI II (18) 2007 1991–1997 201 55 12 100 100 (0) 0 44 (NR) 122
COURAGE (15) 2007 1991–2004 2,287 61 15 38 96 (0) 90 31 (7) 54
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September 9, 2008:894–904 PCI Versus Medical Treatment: Meta-AnalysisPatients with acute coronary syndromes were excluded
rom the studies included in this meta-analysis. However,
ll but 1 trial (23) had included patients with previous
yocardial infarction in a proportion ranging from 25% to
00%. In 4 of the 5 trials that included only patients with
revious myocardial infarction (16,24,25,32), myocardial
nfarction was recent (4 weeks) according to current
uidelines (43). In the remaining trial (18), the time
nterval from myocardial infarction was on average 8
eeks. When calculation regarding all-cause death was
onfined to the 4 trials enrolling patients with recent
yocardial infarction, PCI was associated with an OR of
.65 (95% CI: 0.37 to 1.12) from the random effects
odel and 0.64 (95% CI: 0.40 to 1.05) from the fixed
Lo
g(
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)
Standard Error of Log(Odds Ratio)
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.1 .5 1 5 10
10
100
1000
10000
Figure 2 Assessment of Publication Bias and Relationship
Between Sample Size of the Trial and Treatment Effect
(A) Funnel plot for assessment of publication bias of trials comparing the PCI-
based strategy with medical treatment strategy regarding mortality. The circles
correspond to the treatment effects from individual trials, the red line shows
the summary estimate, and the diagonal lines show the expected 95% confi-
dence intervals around the summary estimate. Note that there is no evident
asymmetry of the points in relation to the summary estimate that might indi-
cate a relevant publication bias. (B) Relationship between sample size of the
trial and treatment effect regarding mortality. Both treatment effect and sample
size are shown on a logarithmic scale. Note the lack of an evident relationship
between sample size and observed treatment effect. PCI  percutaneous coro-
nary intervention.ffects model. When calculation was confined to theemaining 13 trials, PCI was associated with an OR of
.83 (95% CI: 0.65 to 1.04) from the random effects
odel and 0.83 (95% CI: 0.69 to 1.00) from the fixed
ffects model. These results are shown in Figure 4. Figure
also shows the results of 2 additional subset analyses
egarding treatment effect on mortality. The superiority
f PCI was confined to the 14 trials in which coronary
ngiography was required before randomization (14 –
1,23,26,28 –30,32). In addition, the exclusion of the 4
rials in which CABG was allowed as a treatment option
n the PCI-based group (17,24,25,27) did not make any
ifference in treatment effect regarding all-cause mortal-
ty: PCI was associated with an OR of 0.80 (95% CI: 0.64
o 0.99) from the random effects model and 0.80 (95%
I: 0.66 to 0.97) from the fixed effects model.
The cardiac cause of death was reported in 13 trials
14–16,18,20,21,23,25,27–29,32,44). In the PCI group,
15 patients died of cardiac causes compared with 151
atients in the medical treatment group. Allocation to the
CI group was associated with a 26% reduction in the OR
f cardiac death (Fig. 5). There was a slight inconsistency
cross the trials (I2  29%). For the same trials, we
alculated the ORs for noncardiac death. A PCI was
ssociated with an OR of 0.96 (95% CI: 0.67 to 1.36) from
he random effects model and 0.95 (95% CI: 0.73 to 1.24)
rom the fixed effects model.
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ent effects across the trials (I2  56%). A significant
nteraction with treatment effect regarding nonfatal myo-
ardial infarction was observed for the proportion of pa-
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n the PCI group who received stents (p 0.596) or CABG
p  0.362), and proportion of patients in the medical
reatment group who received nonprotocol revascularization
p  0.183)—showed a significant interaction with treat-
ent effect. We also calculated the ORs for the composite
f all-cause death or nonfatal myocardial infarction. A PCI
as associated with an OR of 0.80 (95% CI: 0.60 to 1.05)
rom the random effects model and 0.84 (95% CI: 0.74 to
.96) from the fixed effects model.
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PCI Versus Medical Treatment: Meta-Analysis September 9, 2008:894–904ight have blunted differences in survival between the 2
reatment groups in a way that cannot be predicted. Finally,
ndividual patient data were not available for this study,
hich precluded several subgroup analyses. In particular, we
ere not able to assess the influence of the severity of
schemia at baseline on the potential benefit with PCI.
Another aspect that should be considered is that enroll-
ent of patients was extended over a 17-year period, time in
hich major developments have been recorded in both the
harmacological and the interventional treatment of coro-
ary artery disease. In fact, the year of completion of patient
nrollment did not have a significant impact on the overall
esult as shown by the meta-regression analysis. Obviously,
atients of both study arms have benefited from advances in
rug therapy. Bare-metal stents were used in less than
ne-half of the patients included in the present meta-
nalysis, and drug-eluting stents were implanted in an
rrelevant number of patients. Although no advantage in
urvival has been attributed to both bare-metal and drug-
luting stents (46,47), this does not exclude that future
dvances in both pharmacological and interventional
reatment of patients with coronary artery disease may
educe or further accentuate the difference in mortality
bserved in this meta-analysis.
Well-defined inclusion criteria relevant to the question to
e addressed and a comprehensive accounting for all studies
eeting those criteria are crucial to the success of the
eta-analysis. The present meta-analysis intended to in-
lude all studies that investigated the relative merits of PCI
n patients with stable coronary artery disease and symptoms
r signs of ischemia. Two randomized trials have evaluated
he role of PCI patients with persistent occluded infarct-
elated vessels after myocardial infarction, mostly without
ny clues of ischemia (22,31). In essence, this was done with
he objective of assessing the open artery hypothesis. The
resent meta-analysis did not include the latter 2 trials
ecause of the absence of an ischemia criterion. The same
as done by Katritsis and Ioannidis in their initial (12) and
pdated (13) version of the meta-analysis. On the other
ide, we included all 4 trials that enrolled stable post-recent
nfarct patients with symptoms or signs of ischemia
16,24,25,32). Only 3 of these trials (16,25,32) were in-
luded in the meta-analysis by Katritsis and Ioannidis (13).
e included all 4 trials that used CABG instead of PCI in
0% to 41% of the patients in the PCI-based strategy group
17,24,25,27). In these trials, the form of invasive treatment
herapy was selected after randomization, and their exclu-
ion from our meta-analysis would have violated the
ntention-to-treat principle. Katritsis and Ioannidis (13)
ncluded only 1 of these studies (25) in their meta-analysis.
hus, the present study constitutes a consistent and com-
rehensive investigation of available evidence by meta-
nalytical methods.
There is little doubt that PCI relieves ischemia and
mproves the exercise capacity of patients with angina
ectoris (48). The results of this meta-analysis add signifi- tantly to the value of the PCI-based strategy because they
ontain the novel finding of a substantial reduction of
ong-term mortality by the use of this strategy. A reduction
f similar magnitude (20%) in patients with stable coronary
rtery disease has not been a frequent finding of clinical
rials in the past. Meta-analyses pooling the results of
andomized trials on secondary prevention in patients with
oronary artery disease have shown a reduction of all-cause
eath of 16% with statins (49) and 23% with beta-blockers
50). Nevertheless, the marginal significance level achieved
n the present analysis of mortality may still require the
erformance of a large mortality trial to confirm the poten-
ial superiority of the PCI strategy in patients with stable
oronary artery disease.
A PCI of significant coronary artery stenoses may reduce
he risk of death by improving regional blood flow and
tabilizing the underlying plaque through neointima forma-
ion that occurs after arterial wall injury. The risk of cardiac
eath was also reduced in our pooled analysis of the 13 trials
hat reported this event, although the lack of the informa-
ion in 4 trials might have reduced the significance of this
nding. The risk of nonfatal myocardial infarction was only
lightly decreased. Interestingly, more recent trials showed a
reater reduction in the risk of nonfatal myocardial infarc-
ion, probably because of improvements in the PCI tech-
ology and experience as well as in adjunct antithrombotic
herapy. Whereas there was consistency across trials in the
reatment effect size regarding all-cause mortality, there was
slight inconsistency with respect to cardiac death and a
oderate inconsistency regarding myocardial infarction.
his is a new clue of both the difficulties arising from
ooling together results that partly depend on event defini-
ion and the robustness of all-cause mortality as an end
oint in the evaluation of treatment strategies. However,
lthough the slight decrease in the risk of nonfatal myocar-
ial infarction should not be overstated, even the lack of an
ncreased risk of this adverse event in the PCI group may be
onsidered a positive finding when combined with the
educed overall mortality observed with this strategy. Ap-
arently, the PCI-based strategy is associated with a re-
uced risk of large myocardial infarctions leading to cardiac
eath, and, at least no increase in the long-term risk of
maller, nonfatal myocardial infarctions despite the known
nding of myocardial injury that some patients incur early
fter the procedure.
onclusions
hese findings suggest that a PCI-based invasive strategy
ay improve long-term survival compared with a medical
reatment-only strategy in patients with stable coronary
rtery disease. This justifies the performance of a new
andomized clinical trial sufficiently powered for evaluating
he impact of PCI on long-term mortality.
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